Results 121 to 130 of about 817,997 (230)

The Role of Astrocytes in the Inflammatory Response in Neurodiseases

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Reactive astrocyte‐mediated pathogenic mechanisms in neurodegenerative diseases Schematic representation of key astrocytic pathways contributing to pathology in the pathogenesis of AD, PD, ALS, and HD. In AD, astrocytes exhibit Aβ plaque‐associated activation characterized by GFAP/S100β upregulation, accompanied by impaired EAAT2‐mediated glutamate ...
Shijun Peng   +3 more
wiley   +1 more source

Neurodegenerative Diseases: Epidemiology, Risk Factors, Classification, Pathophysiology, Clinical Features, Diagnosis, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He   +4 more
wiley   +1 more source

Three Dimensional Pharmacophore Modelling of Monoamine oxidase-A (MAO-A) inhibitors

open access: yes, 2007
Flavoprotein monoamine oxidase is located on the outer membrane ofmitochondria. It catalyzes oxidative deamination of monoamine neurotransmitters such asserotonin, norepinephrine and dopamine and hence is a target enzyme for antidepressantdrugs.
Rama Mukherjee   +3 more
core   +1 more source

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou   +9 more
wiley   +1 more source

The use of monoamine oxidase inhibitors in psychiatric practice

open access: yes
This Position Statement provides clinicians with practical advice in relation to the use of monoamine oxidase inhibitors (MAOIs) in treating adult patients with moderate-to-severe depression or anxiety disorders.
Baldwin, David   +6 more
core   +1 more source

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang   +15 more
wiley   +1 more source

New Monocyclic Terpenoid Lactones from a Brown Algae Sargassum macrocarpum as Monoamine Oxidase Inhibitors. [PDF]

open access: yesPlants (Basel), 2022
Kwon J   +10 more
europepmc   +1 more source

Monoamine oxidase isoform-dependent tautomeric influence in the recognition of 3,5-diaryl pyrazole inhibitors.

open access: yes, 2007
Monoamine oxidases (MAO, EC 1.4.3.4), widely distributed in all living organisms, are FAD-containing enzymes, tightly bound to the outer mitochondrial membrane. In mammals, two different isoforms of MAOs are present, namely, MAO-A and MAO-B.
ORTUSO F   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy